Detalhe da pesquisa
1.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol;
24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36528035
2.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol;
22(12): 1705-1720, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34774221
3.
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Eur J Haematol;
105(1): 47-55, 2020 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32145118
4.
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
BMC Cancer;
18(1): 1117, 2018 Nov 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30442119
5.
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.
medRxiv;
2024 Apr 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38699307
6.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine;
60: 102017, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37396807
7.
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results.
Front Oncol;
12: 844779, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35646628
8.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol;
40(27): 3120-3131, 2022 09 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35666982
9.
MRD Assessment in Multiple Myeloma: Progress and Challenges.
Curr Hematol Malig Rep;
16(2): 162-171, 2021 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33950462
10.
When and How to Treat Relapsed Multiple Myeloma.
Am Soc Clin Oncol Educ Book;
41: 358-375, 2021 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34010043
11.
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
Leuk Res;
101: 106497, 2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33385697
12.
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients.
Clin Cancer Res;
27(13): 3695-3703, 2021 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33926915
13.
Whole-genome sequencing analysis of semi-supercentenarians.
Elife;
102021 05 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33941312
14.
New drugs in early development for treating multiple myeloma: all that glitters is not gold.
Expert Opin Investig Drugs;
29(9): 989-1004, 2020 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32434394
15.
Moving Toward Continuous Therapy in Multiple Myeloma.
Clin Hematol Int;
1(4): 189-200, 2019 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34595430
16.
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies.
Cancers (Basel);
11(12)2019 Dec 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31847174
17.
Checkpoint inhibitors and myeloma: promises, deadlocks and new directions.
Ann Transl Med;
8(12): 777, 2020 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32647702